Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Gut - 1 Dec 2012

Hueber Wolfgang, Sands Bruce E, Lewitzky Steve, Vandemeulebroecke Marc, Reinisch Walter, Higgins Peter D R, Wehkamp Jan, Feagan Brian G, Yao Michael D, Karczewski Marek, Karczewski Jacek, Pezous Nicole, Bek Stephan, Bruin Gerard, Mellgard Bjoern, Berger Claudia, Londei Marco, Bertolino Arthur P, Tougas Gervais, Travis Simon P L

Abstract excerpt

OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn's dis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Infusions, Intravenous

Share to Interleukin-17

Share to Leukocyte L1 Antigen Complex

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 22595313
DOI: 10.1136/gutjnl-2011-301668
PMCID: PMC4902107

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22595313-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.PMID 22595313Read ↗

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.Semantic proximity Read ↗

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsSemantic proximity Read ↗

Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.Semantic proximity Read ↗

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.Semantic proximity Read ↗

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.Semantic proximity Read ↗

Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.Semantic proximity Read ↗

ANCA-associated vasculitis following secukinumab treatment for psoriasis: Expanding the Spectrum of IL-17A Inhibitor-Related Autoimmunity— A Case ReportSemantic proximity Read ↗

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.Semantic proximity Read ↗

Comparative Effectiveness and Safety of Ustekinumab versus Anti–TNF Therapy in Crohn Disease: A Systematic ReviewSemantic proximity Read ↗

Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study.Semantic proximity Read ↗

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.Semantic proximity Read ↗

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.